eMedicine Specialties > Neurology > Neuro-vascular Diseases

Foix-Alajouanine Syndrome

Author: Cheryl Ann Palmer, MD, Professor, Departments of Pathology and Neurology, University of Alabama at Birmingham School of Medicine; Consulting Staff, Departments of Pathology and Neurology, University of Alabama at Birmingham Hospital; Consulting Staff, Departments of Pathology and Neurology, Veteran Affairs Medical Center; Consulting Staff, Department of Pathology, Children's Hospital of Alabama
Contributor Information and Disclosures

Updated: Dec 10, 2008

Introduction

Background

Foix and Alajouanine first described Foix-Alajouanine syndrome in 2 young men (aged 31 and 37 y) in 1926.1 The patients presented with subacute myelopathy, and autopsy revealed spinal cord necrosis and abnormally dilated and tortuous vessels situated primarily on the spinal cord surface. The underlying pathology was believed to be a dural arteriovenous (AV) fistula. Krause first attempted surgical treatment in 19112 , performing a laminectomy to expose the abnormal segments of the spinal cord.

Historically eponymic, the syndrome now has many other names in the literature — angiodysgenetic necrotizing myelopathy, subacute necrotizing myelopathy, and venous congestive myelopathy.3

Pathophysiology

Foix-Alajouanine syndrome is an arteriovenous malformation of the spinal cord predominantly affecting the lower thoracic and/or lumbosacral levels; cervical cord involvement is rare. Findings include necrosis of the affected cord regions. Grey matter (as compared to white matter) structures are more severely involved. Masses of enlarged, tortuous, and thick-walled subarachnoid veins are observed overlying the surface of the cord (primarily on the posterior aspect). Smaller blood vessels with thickened fibrotic walls also are present within the affected spinal cord segments.

The enlarged, abnormal veins are associated with dural arteriovenous (AV) shunt or fistulas, usually intradurally but rarely extradurally. These AV shunts are associated with reflux of arterial blood into the venous drainage of the cord. This results in increased venous pressure in the affected regions of the spinal cord, often leading to ischemic injury.4

Frequency

United States

Foix-Alajouanine syndrome is a rare entity. No specific statistics are available, but the condition is likely underdiagnosed.

International

Foix-Alajouanine syndrome also is rare internationally.

Mortality/Morbidity

  • Foix-Alajouanine syndrome is a subacute disorder that gradually evolves over 1-5 years.4
  • Affected patients initially are spastic but eventually develop flaccid paralysis of the limbs and may become wheelchair bound.
  • Death can occur with terminal sepsis or other sequelae.

Race

No racial predilection has been observed.

Sex

Male-to-female ratio is nearly 5:1.5

Age

Foix-Alajouanine usually occurs in older patients (>50 y).4 Patients younger than 30 years are rarely reported.

Clinical

History

  • Patients present with increasing unilateral and/or bilateral weakness, dysesthesias, and numbness or tingling in the lower extremities, which may be symmetric or asymmetric.
  • Early problems with bowel, bladder, and sexual function are common.
  • Symptoms begin after brief exertion as a heavy feeling in the legs that generally improves with rest.
  • Symptoms gradually worsen over months, and the patient may have difficulty standing for long periods.
  • Frequent falls can be a problem.
  • Urinary and fecal incontinence eventually appear.
  • Complaints of nonradiating lower back pain in the lumbosacral or coccygeal regions are common. This may be initially interpreted as sciatica.
  • Weakness or numbness eventually can progress to the upper extremities.
  • An acute onset of symptoms is reported in a minority of patients; a protracted course over a few years is more common in most patients before a diagnosis is made.5

Physical

  • Neurologic examination reveals an alert patient with normal mentation.
  • Normal mental status, speech, and language and cranial nerve function are generally present.
  • Unsteadiness of gait, which also may be halting in nature but on a narrow base, is common.
  • Spastic or flaccid paraparesis and a sensory level below the lesion can be observed.
  • Deep tendon reflexes may be normal or increased.
  • Bilateral Babinski signs may be present, as may clonus. Upper motor neuron and lower motor neuron signs may be seen simultaneously.5
  • Vibration and joint position senses usually are preserved.
  • Rectal sphincter tone frequently is diminished.

Causes

  • The etiology of this syndrome is not well understood.
    • Most patients have an arteriovenous (AV) fistula in the lower thoracic dura.
    • One hypothesis is that the higher arterial pressure within the dura is transmitted to the spinal venous plexus via the intradural venous system, compromising perfusion and leading to infarction of the spinal cord parenchyma. Arterial blood originating from the dural fistula enters the venous system, increasing pressure and impairing normal drainage from the cord parenchyma.3
    • Thrombosis may occur but not until late in the course of the disease.
    • Venous stasis, not thrombosis, may be the primary cause of infarction. The preferential involvement of the distal cord is presumably due to orthostasis.
  • The onset in middle age suggests that the syndrome is acquired, in contrast to other arteriovenous malformations, which are assumed to be congenital abnormalities, although the specificity for the spinal cord is not easily explained.

More on Foix-Alajouanine Syndrome

Overview: Foix-Alajouanine Syndrome
Differential Diagnoses & Workup: Foix-Alajouanine Syndrome
Treatment & Medication: Foix-Alajouanine Syndrome
Follow-up: Foix-Alajouanine Syndrome
Multimedia: Foix-Alajouanine Syndrome
References

References

  1. Foix CH, Alajouanine T. La myelite necrotique subaigue. Rev Neurol. 1926;46:1-42.

  2. Krause F. Chirurgie des Gehirns und Ruckenmarks nach eigenen Erfarungen. Berlin: Urban & Schwarzenberg; 1911.

  3. Rodriguez FJ, Crum BA, Krauss WE, Scheithauer BW, Giannini C. Venous congestive myelopathy: a mimic of neoplasia. Mod Pathol. May 2005;18(5):710-8. [Medline].

  4. Mishra R, Kaw R. Foix-Alajouanine syndrome: an uncommon cause of myelopathy from an anatomic variant circulation. South Med J. May 2005;98(5):567-9. [Medline].

  5. Jellema K, Tijssen CC, van Gijn J. Spinal dural arteriovenous fistulas: a congestive myelopathy that initially mimics a peripheral nerve disorder. Brain. Dec 2006;129:3150-64. [Medline].

  6. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 12-1992. A 64-year-old woman with the abrupt onset of paraparesis after 10 months of increasing episodic leg weakness. N Engl J Med. Mar 19 1992;326(12):816-24. [Medline].

  7. Criscuolo GR, Oldfield EH, Doppman JL. Reversible acute and subacute myelopathy in patients with dural arteriovenous fistulas. Foix-Alajouanine syndrome reconsidered. J Neurosurg. Mar 1989;70(3):354-9. [Medline].

  8. Graham DI, Lantos PL, eds. Foix-Alajouanine syndrome. In: Greenfield's Neuropathology. 6th ed. York, NY: Oxford Univ Press; 1997:1101-1104.

  9. Kneisley LW, Dominguez MR, Bignami A, Rossier AB. Paraplegia following surgery in Foix and Alajouanine syndrome. (Arteriovenous malformation of the spinal cord). Paraplegia. Feb 1980;18(1):33-41. [Medline].

  10. Koeppen AH, Barron KD, Cox JF. Foix-Alajouanine syndrome. Acta Neuropathol (Berl). 1974;29(3):187-97. [Medline].

  11. Minami S, Sagoh T, Nishimura K, et al. Spinal arteriovenous malformation: MR imaging. Radiology. Oct 1988;169(1):109-15. [Medline].

  12. Schmidbauer M, Lassmann J, Pilz P, et al. Subacute diencephalic angioencephalopathy: an entity similar to angiodysgenetic necrotizing encephalopathy and Foix-Alajouanine disease. J Neurol. Aug 1992;239(7):379-81. [Medline].

  13. Welsh CT, Palmer CA, Townsend JJ. Radiologic pathologic correlation of spinal dural arteriovenous fistula (Foix-Alajouanine syndrome). Int J Neurorad. 1998;4 (1):51-55.

  14. Wrobel CJ, Oldfield EH, Di Chiro G, et al. Myelopathy due to intracranial dural arteriovenous fistulas draining intrathecally into spinal medullary veins. Report of three cases. J Neurosurg. Dec 1988;69(6):934-9. [Medline].

  15. Zweifler RM. Management of acute stroke. South Med J. Apr 2003;96(4):380-5. [Medline].

Further Reading

Keywords

angiodysgenetic necrotizing myelopathy, spinal dural arteriovenous fistula, subacute necrotizing myelopathy, venous congestive myelopathy, spinal cord necrosis, dural arteriovenous fistula, AV malformation of the spinal cord, spinal cord malformation, laminectomy

Contributor Information and Disclosures

Author

Cheryl Ann Palmer, MD, Professor, Departments of Pathology and Neurology, University of Alabama at Birmingham School of Medicine; Consulting Staff, Departments of Pathology and Neurology, University of Alabama at Birmingham Hospital; Consulting Staff, Departments of Pathology and Neurology, Veteran Affairs Medical Center; Consulting Staff, Department of Pathology, Children's Hospital of Alabama
Cheryl Ann Palmer, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuropathologists, Medical Association of the State of Alabama, Society for Neuro-Oncology, and Southern Medical Association
Disclosure: Nothing to disclose.

Medical Editor

Richard M Zweifler, MD, Chief of Neurology, Sentara Healthcare, Norfolk, VA
Richard M Zweifler, MD is a member of the following medical societies: American Academy of Neurology, American Heart Association, American Medical Association, American Stroke Association, Royal Society of Medicine, and Stroke Council of the American Heart Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Howard S Kirshner, MD, Professor of Neurology, Psychiatry and Hearing and Speech Sciences, Vice Chairman, Department of Neurology, Vanderbilt University School of Medicine; Director, Vanderbilt Stroke Center; Program Director, Stroke Service, Vanderbilt Stallworth Rehabilitation Hospital; Consulting Staff, Department of Neurology, Nashville Veterans Affairs Medical Center
Howard S Kirshner, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, American Heart Association, American Medical Association, American Neurological Association, American Society of Neurorehabilitation, National Stroke Association, Phi Beta Kappa, and Tennessee Medical Association
Disclosure: Boehringer Ingelheim Honoraria Speaking and teaching; BMS/Sanofi Honoraria Speaking and teaching; Pfizer Honoraria Speaking and teaching; Novartis Consulting fee Review panel membership

CME Editor

Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital
Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association
Disclosure: Nothing to disclose.

Chief Editor

Helmi L Lutsep, MD, Professor, Department of Neurology, Oregon Health and Science University; Associate Director, Oregon Stroke Center
Helmi L Lutsep, MD is a member of the following medical societies: American Academy of Neurology and American Stroke Association
Disclosure: Co-Axia Consulting fee Review panel membership; Talecris Consulting fee Review panel membership; AGA Medical Consulting fee Review panel membership; Boehringer Ingelheim Honoraria Speaking and teaching; Boston Scientific Honoraria Speaking and teaching; Concentric Medical None Review panel membership; Northstar Neuroscience  Review panel membership; ev3 Consulting fee Review panel membership

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.